
In this article 15 sections
- What Happened in March 2026: The Semaglutide Patent Expiry in Simple W...
- Can a PCD Franchise Sell Semaglutide? The Honest Answer
- Why the Semaglutide Buzz Is Still Good News for Your Cardio-Diabetic B...
- The Cardio-Diabetic Molecules That Are Actually Moving in 2026
- Dosage Forms That Work Best in a Cardio-Diabetic Range
- Price Control, Margins and the Reality of Selling Chronic Medicines
- How Doctors Are Prescribing After the GLP-1 Wave
- Starting a Cardio-Diabetic PCD Franchise in 2026: Step by Step
- Getting Your Own Cardio-Diabetic Brand Made Through Third-Party Manufa...
- Common Mistakes Franchise Partners Make in the Cardio-Diabetic Segment
- Where the Opportunity Is Strongest by Region
- Quick Checklist Before You Sign a Cardio-Diabetic Franchise Deal
- Related Ranges Worth Adding Alongside Cardio-Diabetic Products
- Frequently Asked Questions
- Find Your Cardio-Diabetic PCD Partner on Apromart
If you run a PCD pharma franchise or you are planning to start one, 2026 has handed you a once-in-a-decade talking point. On 20 March 2026 the Indian patent on semaglutide, the molecule behind Ozempic and Wegovy, expired. Within a day, Indian drug makers had generic versions on pharmacy shelves, and prices fell sharply. Doctors, chemists and patients are now asking about diabetes and weight management in a way they never did before.
This guide is written for distributors, PCD franchise owners, stockists and medical representatives who want to understand what this shift actually means for their business. We will look at what changed, what you can and cannot sell through a franchise model, which parts of the cardiac and diabetic PCD range are growing fastest, and how to pick a reliable company to partner with. We have kept it practical, based on what distributors and field staff are actually seeing in the market.
What Happened in March 2026: The Semaglutide Patent Expiry in Simple Words
Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. These drugs help the body release insulin after meals, slow stomach emptying and reduce appetite. For years, only the innovator company could sell it in India, and the monthly cost of therapy was out of reach for most patients.
Once the patent lapsed, Indian companies that already held approval from the drug regulator moved fast. Business Today reported that local manufacturers could now legally make and sell their own versions without a licence from the original patent holder. Sun Pharma, Dr Reddy's, Zydus, Glenmark, Natco with Eris, Alkem and several others announced launches within days. Reports put the starting price of some generic options at around Rs 1,300 a month, against the earlier band of roughly Rs 8,800 to Rs 10,000 for the branded product.
Outlook Business described it as a race involving close to fifty brands. That number tells you one thing very clearly: semaglutide itself is going to be a crowded, price-driven market dominated by large companies with their own manufacturing, cold chain and big field forces.
Can a PCD Franchise Sell Semaglutide? The Honest Answer
Almost every distributor who calls us this year has asked this. In most cases the answer is no, at least not for now, and the reasons are fairly simple.
- It is a biological-style peptide injection. Making semaglutide needs specialised synthesis or recombinant technology, sterile pen-filling lines and strict cold-chain storage between 2 and 8 degrees Celsius. Very few contract manufacturers in India have this capability.
- Approval is product-specific. Every company that launched in March already held approval from the Central Drugs Standard Control Organisation. A franchise company cannot simply ask its third-party plant to start producing it.
- It is a prescription-only medicine with a serious safety profile. Doctors need dose titration support, patient counselling and pharmacovigilance. That is not a model that fits a small territory distributor carrying a general range.
- Price competition is brutal. When big brands are cutting prices by 60 to 90 percent, there is little margin left for a franchise layer.
So if someone offers you a "semaglutide PCD franchise" with monopoly rights at a cheap price, ask hard questions. Ask for the manufacturing licence, the product approval and the cold-chain plan in writing. If they cannot show it, walk away.
That does not mean you have missed the bus. The money for franchise partners is in the medicines that sit around semaglutide in the same prescription.
Why the Semaglutide Buzz Is Still Good News for Your Cardio-Diabetic Business
Picture a normal OPD day in a district town. A patient walks in having read about "the new diabetes injection" on social media. The doctor runs an HbA1c test, checks blood pressure, checks lipids and kidney function. Many of these patients are newly diagnosed or have poorly controlled sugar. Most of them will not be put on semaglutide immediately. They will be started or continued on oral therapy, statins, blood pressure medicines and supportive products.
In other words, the semaglutide headlines are pulling more people into diabetes and heart care. Every new patient who enters the system becomes a long-term user of the oral medicines that a PCD franchise can legitimately supply. The awareness wave lifts the whole category.
The sales data points the same way. Industry tracker data reported by Ind-Ra showed the Indian pharma market growing 12.1 percent in July 2026, with the cardiac segment growing 14.9 percent. Cardiac is now one of the fastest-moving therapy areas in the domestic market, and diabetes sits right beside it in the same prescriptions. Chronic therapy also means repeat purchases month after month, which is the most valuable kind of sale for a distributor.
There is a catch, though. The same data showed anti-diabetic sales growing only about 5.8 percent. That slower figure is not a sign of falling demand. It reflects heavy price erosion as more molecules go generic and as government price controls bite. Volume is rising, but value per strip is falling. For a franchise partner, that means two things: you need a wider basket of products to protect your margins, and you need a company that prices sensibly rather than one that simply promises the lowest rate.
The Cardio-Diabetic Molecules That Are Actually Moving in 2026
When you speak to a cardiologist, diabetologist or general physician in a tier-2 or tier-3 town, these are the groups that come up again and again. Each of them is available in oral dosage forms that reputed third-party pharma manufacturers already produce for franchise companies.
1. SGLT2 inhibitors and their combinations
Dapagliflozin and empagliflozin became widely available as affordable generics over the last few years. Doctors like them because they lower sugar and also protect the heart and kidneys. Combinations with metformin, sitagliptin or linagliptin are now routine prescriptions. If a franchise company does not carry at least one SGLT2 molecule and a couple of combinations, its diabetic range is already outdated.
2. DPP-4 inhibitors (gliptins)
Sitagliptin, vildagliptin, teneligliptin and linagliptin remain workhorses, especially in combination with metformin. Teneligliptin is popular in price-sensitive markets. These are high-volume products where reliable supply matters more than flashy packaging.
3. Metformin in sustained and extended release forms
Metformin is still the first step for most patients. Doctors increasingly prefer SR and ER versions because they cause fewer stomach complaints. Glimepiride plus metformin and voglibose combinations also continue to sell well in many regions.
4. Statins and lipid control
Rosuvastatin and atorvastatin, alone or combined with fenofibrate, ezetimibe or aspirin, are standard for diabetic patients with cardiovascular risk. These are excellent "attach" products because almost every diabetic patient above forty ends up on one.
5. Blood pressure medicines
Telmisartan and its combinations with amlodipine, hydrochlorothiazide, chlorthalidone or metoprolol are among the most prescribed cardiac products in the country. Cilnidipine, olmesartan and the newer azilsartan also have strong pockets of demand.
6. Antiplatelets and heart failure support
Clopidogrel, aspirin combinations, ticagrelor and the sacubitril-valsartan combination for heart failure are growing as more patients receive cardiac care in district hospitals and private nursing homes.
7. Supportive and nutraceutical products
Diabetic neuropathy is common, so methylcobalamin, alpha lipoic acid, benfotiamine and pregabalin combinations sell steadily. Diabetic-friendly protein powders and fibre supplements are another growing line. You can explore partners for these on the nutraceutical PCD companies page.
A sensible cardio-diabetic portfolio for a new franchise usually starts with 40 to 70 products across these groups, then grows as the doctor base expands.
Dosage Forms That Work Best in a Cardio-Diabetic Range
Most chronic cardio-diabetic therapy is oral, and that suits the franchise model well. Here is how the dosage mix typically looks:
- Tablets make up the bulk of the range: plain, film-coated, sustained-release and bilayer tablets for fixed-dose combinations. See listed suppliers in the tablets range.
- Capsules are used for some supportive and nutraceutical products, such as methylcobalamin and omega-3 combinations. Browse the capsules range.
- Sachets and powders work well for diabetic nutrition, fibre and protein supplements. See the sachets range and protein powder range.
- Injectables such as insulin and GLP-1 products need cold chain and special licences. Unless your company already handles this, it is better to stay with oral products in the early years. Established suppliers are listed in the injectables range.
Bilayer tablets deserve a special mention. Many modern combinations, such as metformin SR with a gliptin or glimepiride, are made as bilayer tablets so that each drug releases at the right speed. Not every plant has bilayer compression machines, so if you plan to get your own brand made, check this capability before signing with a tablet third-party manufacturer.
Price Control, Margins and the Reality of Selling Chronic Medicines
Many cardio-diabetic molecules fall under the Drugs (Prices Control) Order, and the National Pharmaceutical Pricing Authority fixes ceiling prices for scheduled formulations. You can check current ceiling prices on the NPPA website. For a franchise partner this has three practical effects.
First, the MRP of many products is capped, so the margin comes from the difference between your purchase rate and the trade price, not from inflating the MRP. A company that offers suspiciously high MRPs on scheduled drugs is putting you at risk.
Second, non-scheduled combinations and supportive products usually give better margins. A balanced range that mixes price-controlled essentials with well-chosen combinations and nutraceuticals keeps your overall margin healthy.
Third, because chronic patients buy every month, a lower margin on a high-volume product can still earn more than a high margin on something that sells twice a year. Track repeat sales per doctor, not just the margin per strip.
How Doctors Are Prescribing After the GLP-1 Wave
Talk to field staff working in Punjab, Haryana, Gujarat, Uttar Pradesh or Maharashtra and a few patterns stand out in 2026.
- Earlier screening. Patients are asking for sugar and lipid tests on their own, so more people are being diagnosed in their thirties and forties.
- Weight is now part of the conversation. Even when doctors do not prescribe GLP-1 injections, they discuss weight loss and lean towards medicines that are weight-neutral or help with weight, such as SGLT2 inhibitors.
- Combination prescribing. Doctors want fewer pills for the patient, so fixed-dose combinations of gliptins, SGLT2 inhibitors and metformin are rising.
- Kidney and heart protection. Cardiologists and nephrologists are prescribing SGLT2 inhibitors even for some patients without diabetes, which widens the market.
- Trust and quality. After several drug quality scares, doctors care more about which company stands behind the product. A visible WHO-GMP certificate and clean batch records help your representatives open doors.
Starting a Cardio-Diabetic PCD Franchise in 2026: Step by Step
If you are new to this segment, here is a practical path that many successful distributors follow.
Step 1: Study your territory
Count the diabetologists, cardiologists, physicians and nursing homes in your district. Visit a few chemists and ask which cardio-diabetic brands move fastest. You will quickly see which molecules are in demand and where existing companies are weak.
Step 2: Get your licences in order
You will need a wholesale drug licence (Form 20B and 21B), GST registration and, in most cases, a registered pharmacist or experienced person on record. Your state drug control department handles the drug licence.
Step 3: Shortlist franchise companies
Use a portal like Apromart to compare companies that focus on this therapy. Start with the cardiac and diabetic PCD pharma companies list, then check whether they also offer a general range so that you can serve physicians with antibiotics, gastro products and pain relief as well.
Step 4: Verify before you pay
Ask for the manufacturing site's WHO-GMP certificate, the drug manufacturing licence, sample certificates of analysis and the full product list with composition. Confirm that each product with a new combination has the required approval. The CDSCO website publishes lists of approved new drugs and banned fixed-dose combinations, which is useful for cross-checking.
Step 5: Agree on monopoly rights in writing
Monopoly means no other distributor of the same company gets your area for the agreed products. Get the territory, product list, minimum order value and duration written into the agreement.
Step 6: Start with a focused list
Do not order 150 products on day one. Start with 30 to 50 fast movers, build relationships with 15 to 25 doctors, and add products as prescriptions come in.
Step 7: Plan your promotional input
Visual aids, product cards, sample packs and reminder gifts help representatives get time with doctors. Ask the company what promotional support it gives and how it complies with the Uniform Code for Pharmaceutical Marketing Practices 2024, which limits gifts and sponsored travel for doctors.
Getting Your Own Cardio-Diabetic Brand Made Through Third-Party Manufacturing
Some distributors grow to a point where they want their own brand name on the box. That is where third-party pharma manufacturing comes in. You choose the molecules and brand names, and a licensed plant manufactures them for you under its licence, often called loan licence or contract manufacturing.
For cardio-diabetic products, keep these points in mind:
- Revised Schedule M compliance. From 1 January 2026, the upgraded Good Manufacturing Practice rules apply to every manufacturing unit in India, including small and medium plants. Only work with plants that have upgraded and can show you inspection readiness.
- Stability data. Sustained-release and bilayer products need proper stability studies so that the medicine works until its expiry date. Ask for the stability summary of each product.
- Minimum order quantity. Most plants ask for a minimum batch, often 10,000 to 50,000 strips or more per product. Plan your cash flow around it.
- Brand name checks. Search for similar names before you finalise, so that you do not face trademark disputes or confuse chemists with look-alike names.
- Packaging and artwork. Make sure the label carries all mandatory information, including the QR code requirement for APIs and any product-level rules that apply to your products.
Apromart lists suppliers by dosage form, so you can compare a tablet third-party manufacturer, a capsule third-party manufacturer and a nutraceutical third-party manufacturer side by side.
Common Mistakes Franchise Partners Make in the Cardio-Diabetic Segment
- Chasing the trending molecule only. One hot product will not build a business. Doctors want a complete therapy range from one reliable company.
- Ignoring the follow-up. Chronic therapy depends on patients returning every month. Keep stock steady at chemists close to your key doctors so refills are never missed.
- Buying on price alone. The cheapest rate often comes with weak quality systems. One failed batch or recall can damage your name with doctors for years.
- Skipping documents. Always keep invoices, batch numbers and certificates of analysis on file. Drug inspectors can ask for them at any time.
- Overpromising to doctors. Do not claim that a tablet works like a GLP-1 injection or promise weight loss that the label does not support. Stick to approved uses.
Where the Opportunity Is Strongest by Region
Diabetes and heart disease are rising everywhere, but some markets stand out for franchise partners. Southern states such as Tamil Nadu, Kerala and Karnataka have very high diabetes prevalence and a mature prescription culture. Punjab, Haryana and Delhi NCR combine high prevalence with strong private healthcare. Uttar Pradesh, Bihar, Madhya Pradesh and Rajasthan have huge populations where awareness is growing fast and competition is still thinner in smaller towns.
Manufacturing hubs also matter. Baddi in Himachal Pradesh, Haridwar in Uttarakhand, Ahmedabad in Gujarat and the Chandigarh tri-city area of Chandigarh, Panchkula and Mohali host many of the plants and franchise companies listed on Apromart. Being close to these hubs can mean faster dispatch and easier factory visits.
Quick Checklist Before You Sign a Cardio-Diabetic Franchise Deal
- Does the company carry at least one SGLT2 inhibitor, two or three gliptin combinations and metformin SR options?
- Are statins, telmisartan combinations and antiplatelets part of the same list, so a cardiologist can prescribe a full regimen?
- Can the company show the WHO-GMP certificate and the Revised Schedule M status of the plant for each product?
- Are MRPs of price-controlled drugs within the NPPA ceiling?
- Is the monopoly territory, minimum order and agreement period clearly written down?
- What is the average dispatch time to your city, and who pays for freight?
- Does the company offer visual aids, product literature and sample packs that follow the UCPMP 2024 rules?
- Can you speak to two or three existing distributors before you commit?
If the answers to most of these are yes, you are likely dealing with a serious company. If several answers are vague, keep looking.
Related Ranges Worth Adding Alongside Cardio-Diabetic Products
Patients with diabetes and heart disease often need care from more than one speciality. Adding a few related lines helps you get more value from every doctor visit:
- Gastro range for acidity and digestive problems common with multiple medicines.
- Neuro range for diabetic neuropathy and nerve pain.
- Ortho range for joint pain and calcium and vitamin D support.
- Ophthalmic range since diabetic eye problems are frequent.
- Derma range for fungal infections, which are more common in people with diabetes.
Frequently Asked Questions
Can I get a PCD franchise for generic semaglutide?
It is rare. Semaglutide needs product-specific approval, cold-chain handling and specialised manufacturing, so it is mostly sold by large companies through their own field force. Treat any cheap semaglutide franchise offer with caution and ask for approval documents.
Which cardio-diabetic products are best for a new PCD franchise?
Start with metformin SR combinations, gliptins, SGLT2 inhibitors and their combinations, telmisartan and amlodipine combinations, rosuvastatin and atorvastatin, clopidogrel and a few neuropathy supplements. These have steady monthly demand.
How much investment is needed for a cardio-diabetic PCD franchise?
Many companies accept a first order of about Rs 25,000 to Rs 1,00,000, depending on the number of products and the territory. Add your drug licence costs, storage and field staff salaries to plan your total budget.
Is the anti-diabetic market still growing if sales growth is slower?
Yes. The number of patients and strips sold keeps rising. Value growth looks slower because generic competition and price ceilings have lowered the price per strip. A wide product basket protects your earnings.
Do I need a pharmacist to start a PCD franchise?
A wholesale drug licence usually needs a registered pharmacist or a competent person with relevant experience and qualification. The exact rules depend on your state drug control department.
What does Revised Schedule M mean for my franchise company?
It means every plant making your products must meet upgraded GMP standards from 1 January 2026. Ask your company which plant makes each product and whether it has completed the upgrade.
Can I launch my own brand of diabetic tablets?
Yes. A third-party manufacturer can produce tablets under your brand name. You will need a wholesale licence, a trademark check, approved compositions and enough budget to meet the minimum batch size.
How do I find verified cardio-diabetic PCD companies?
Use the cardiac and diabetic category on Apromart to compare companies, then verify certificates, product lists and references from existing distributors before you sign.
Find Your Cardio-Diabetic PCD Partner on Apromart
Semaglutide will stay in the news for a while. For most franchise partners, though, the monthly income will come from ordinary tablets that patients take every morning and every night. Choose a partner with a modern product list, upgraded manufacturing and honest pricing, and you will have a business that keeps running long after the headlines move on.
Browse the cardiac and diabetic PCD pharma companies, explore other speciality ranges, or post your requirement and let top companies listed from PAN India contact you. Have a question? Contact the Apromart team.




